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The advent of chemotherapy for early-stage breast cancer has ushered in a new age of management for the condition. This article
charts the evolution of chemotherapy for breast cancer, and highlights the current need for carefully planned, fully implemented local
protocols to support the delivery of modern regimens.
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Breast cancer has been recognised since at least 1600 BC, when an
ancient Egyptian medical text (Smith, 2006) described eight cases
of a tumour or ulcer of the breast that were treated by
cauterisation. There followed many historical reports of the
disease, all concluding that there was no cure.
In the seventeenth century, an understanding of the lymphatic
circulation enabled the link to be made between the breast and the
axillary lymph nodes, and led to the first lymph node surgery in
women with breast cancer (Sakorafas, 2008). Radical surgery for
breast cancer reached its zenith in the nineteenth century, at the
hands of the US surgeon William Halsted, who removed not only
the affected breast, but also the contralateral breast, all associated
lymph nodes, and the underlying pectoral muscles (Halsted, 1907).
This morbid and mutilating procedure was deemed necessary to
prevent recurrence, but did little to change the natural history of
the disease.
In the twenty-first century, breast cancer is the most common
cancer in the United Kingdom, with in excess of 45000 women and
around 300 men diagnosed in 2005 (Cancer Research UK, 2009).
However, the past half century has seen the emergence and
evolution of new therapeutic approaches for breast cancer,
including chemotherapy, radiotherapy and conservative surgery
(Figure 1).
THE BIRTH OF CHEMOTHERAPY
After the Second World War, the observation by Goodman and
Gilman that nitrogen mustards had the potential for anticancer
effects (Gilman, 1946), and parallel work on antifolates by Farber
et al (1948), led to the first successful drug treatments for
cancer (Goodman et al, 1984). Subsequently, observations of uracil
uptake by normal rat mucosa and tumours led to the development
of 5-fluorouracil (Heidelberger et al, 1957), and then cyclo-
phosphamideþmethotrexateþ5-fluorouracil (CMF) – the first
effective chemotherapy regimen for breast cancer (Bonadonna
et al, 1976).
CMF was tested in the 1970s by Bonadonna et al (1976) and the
Milan group. Their demonstration that the risk of breast cancer
recurrence after surgery could be reduced with the addition of
adjuvant chemotherapy paved the way for the development of
surgical procedures less morbid than those pioneered by Halsted.
Later, trials from the US National Surgical Adjuvant Breast and
Bowel Project (NSABP) established that a combination of
lumpectomy and radiotherapy was equivalent to mastectomy in
terms of outcome (Fisher et al, 2002).
NEW CHEMOTHERAPY AGENTS
Although the Milan group was the first to describe the use of an
anthracycline (doxorubicin) in metastatic breast cancer (Bona-
donna et al, 1969), the first anthracycline-containing regimen to
become a ‘gold standard’ was doxorubicinþcyclophosphamide
(AC), investigated initially by the NSABP in the 1990s (Fisher et al,
1990). The rationale for including the anthracycline was to reduce
the duration of treatment, the number of hospital visits and the
need for antiemetic medication (classical CMF involves 2 weeks of
oral cyclophosphamide for each cycle, and produces significant
and long-lasting nausea) (Fisher et al, 1990). There was no efficacy
advantage of AC over CMF, possibly because of the shorter
duration of treatment and the elimination of both 5-fluorouracil
and methotrexate from the combination, and over the ensuing
30 years, CMF and AC became references for the development of
newer, more effective chemotherapy regimens on both sides of the
Atlantic.
In early attempts to improve the efficacy of CMF, a number
of investigators tested regimens where, in a 6-cycle regimen,
an anthracycline (doxorubicin or epirubicin) was substituted
for methotrexate to make either FAC (5-FUþdoxorubicinþ
cyclophosphamide) or FEC (5-FUþepirubicinþcyclophosphamide).
Various doses of the drugs have been tested using either the classic
4-weekly schedule or a shortened 3-weekly regimen, which has often
been compared with 3-weekly all intravenous CMF. The FAC regimen
is most commonly 5-FU 500mgm
–2, doxorubicin 50mgm
–2
and cyclophosphamide 500mgm
–2,a l l3w e e k l y( M a r t i net al,
2003). There are several FEC variations, leading to a degree of
confusion when reference is made to the regimen, although there are
several clearly defined schedules including ‘French FEC’ (French
Adjuvant Study Group, 2001) and ‘Canadian FEC’ (Levine et al, 1998).
An alternative to the substitution of methotrexate is the addition
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epirubicin were followed by four cycles of CMF, resulting in
significantly improved efficacy compared with six cycles of CMF
alone (Poole et al, 2006).
In the 1970s, the development of the taxanes, the first new
cytotoxic drugs for several decades with activity in metastatic
breast cancer (Wani et al, 1971), was soon followed by the
inclusion of paclitaxel or docetaxel in various adjuvant che-
motherapy trial regimens (Henderson et al, 2003; Mamounas et al,
2005; Martin et al, 2005; Bear et al, 2006). In the United States, AC
followed by paclitaxel in a block-sequential design was shown to be
more effective than AC alone (Henderson et al, 2003). This
regimen was subsequently ‘accelerated’ – given every 2 weeks
rather than every 3 weeks – an adaptation made possible through
the use of granulocyte colony-stimulating factor, which helped to
prevent chemotherapy-associated neutropenia (Citron et al, 2003).
The accelerated approach resulted in a further increment in
antitumour activity (Citron et al, 2003).
Another major development was marked by the Breast Cancer
International Research Group (BCIRG)-001 trial, in which the
5-fluorouracil component of FAC was replaced by docetaxel, that is,
the TAC regimen (Martin et al, 2005). The trial showed that TAC
provided a significant improvement in efficacy compared with FAC.
The French Adjuvant group modified FEC into a block-sequential
regimen in which three cycles of FEC were followed by three cycles
of docetaxel (FEC-T) (Roche ´ et al, 2006). Since then, FEC-T has
become a commonly used regimen following surgery for axillary
lymph node-positive breast cancer in the United Kingdom.
CURRENT REGIMENS FOR EARLY-STAGE BREAST
CANCER
There is currently no one gold standard regimen in early-stage
breast cancer. The proliferation and diversity of trials, with varying
interpretations of the standard of care, has led to endless
conjecture on the best treatment, and much discussion of the
route by which the ‘latest’ regimen to be tested has evolved.
However, there is general agreement that CMF-like regimens are
better than nothing, that anthracycline-containing regimens are
better than CMF, and that the taxanes further add to the benefit of
anthracyclines (Figure 2; Peto, 2007). The most robust evidence for
this view comes from the Oxford overview of work by the Early
Breast Cancer Trialists’ Collaborative Group, which includes the
details of more than 250000 women randomised into trials of
polychemotherapy in early-stage breast cancer (Peto, 2007).
The latest guidelines on breast cancer management from the
National Institute for Health and Clinical Excellence (NICE)
emphasise the importance of chemotherapy for both early (NICE,
2009a) and advanced disease (NICE, 2009b). More specifically, for
lymph node-positive early or locally advanced breast cancer, NICE
states that docetaxel, not paclitaxel, should be part of the
chemotherapy regimen (NICE, 2009a). NICE also recommends
docetaxel monotherapy in patients with advanced breast cancer in
whom anthracyclines have failed or are contraindicated, and in
combination chemotherapy (e.g., with trastuzumab) in patients
whose tumours overexpress human epidermal growth factor
receptor 2 (HER2) (NICE, 2009b). NICE only recommends the
combination of gemcitabine and paclitaxel as an option for
advanced breast cancer if docetaxel monotherapy or the combina-
tion of docetaxel and capecitabine would also be appropriate. In
the first instance, however, the guideline states that, in the majority
of cases, patients should start treatment with taxane monotherapy
(preferably docetaxel) followed by second-line vinorelbine or
capecitabine monotherapy and then by third-line capecitabine or
vinorelbine monotherapy (NICE, 2009b).
REGIMEN DELIVERY: PRACTICAL AND COST
CONSIDERATIONS
It is incumbent on the NHS to deliver treatments that are found to
be effective in clinical trials, licensed by the European regulatory
authorities and approved by NICE and the Scottish Medicines
Consortium. Almost all NHS breast cancer units now have the
facilities and expertise required to deliver complex chemotherapy
regimens such as TAC. However, challenges remain, notably in
service capacity, management and prevention of neutropenic
complications, and the financial costs of chemotherapy.
Looking first at service capacity, it is clear that as thresholds
for offering chemotherapy fall, the number of patients receiving
treatment will increase. The introduction of trastuzumab as a
routine adjuvant treatment for patients with breast cancers that
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Figure 2 Stepwise improvements in efficacy of chemotherapy for early-
stage breast cancer. Source: Preliminary data presented by R Peto at the
2007 San Antonio Breast Cancer Symposium on behalf of the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG).
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and there is concern that the growth in adjuvant therapies across
cancer care as a whole will put increasing pressure on
chemotherapy day units. Furthermore, there are now at least three
studies, though the data are still preliminary, showing that the
efficacy of standard breast cancer chemotherapy can be improved
by the addition of a 6-monthly zoledronic acid infusion for 3 or 5
years (Coleman et al, 2006; Winter et al, 2008). Such an approach
may save lives, but has the potential to more than double the
number of intravenous treatments delivered to the population of
patients with early-stage breast cancer, hence adding to the strain
on resources.
The prevention and management of neutropenic events are
covered in detail elsewhere in this supplement by Kelly and
Wheatley, (2009); Cullen and Baijal, (2009) and Cameron, (2009).
In summary, recent reports from the National Confidential
Enquiry into Patient Outcome and Death (NCEPOD, 2008) and
the National Chemotherapy Advisory Group (NCAG, 2009) have
highlighted the need for clear, fully implemented local protocols
for predicting, recognising and managing febrile neutropenia and
neutropenic sepsis in patients receiving chemotherapy. In addi-
tion, there is international guidance on the use of G-CSF
prophylaxis of neutropenia (Aapro et al, 2006; Smith et al, 2006).
Looking at the financial considerations, the drug acquisition
cost for the UK-licensed TAC regimen is d6554 for six cycles, based
on list prices, for a woman with a body surface area of 1.8m
2
(excluding VAT and assuming no drug wastage) (BNF, 2009). Six
cycles of FAC for the same woman would cost d1278. Furthermore,
in the BCIRG-001 trial, the febrile neutropenia rate for patients
receiving TAC approached 25% (Martin et al, 2005), well above the
recommended threshold for primary prophylaxis with G-CSF
(Aapro et al, 2006; Smith et al, 2006). If the cost of a standard 6mg
dose of pegylated filgrastim is included, the drug acquisition cost
increases to d10839.
Some cancer networks have adopted FEC-T as a standard for
patients with axillary lymph node-positive breast cancer, despite
the lack of a specific licence for the regimen in the United
Kingdom. The practice may be based on trial data suggesting that
the rate of febrile neutropenia associated with FEC-T is lower than
the 20% threshold for primary G-CSF prophylaxis stipulated by the
international guidelines (Aapro et al, 2006; Roche ´ et al, 2006;
Smith et al, 2006), allowing services to avoid the cost of G-CSF
prophylaxis. However, data from two separate UK studies,
presented at the National Cancer Research Institute’s Cancer
Conference in 2008, do not support such an optimistic view of
FEC-T’s potential for reducing the risk of febrile neutropenia.
Head et al (2008) reported a 25% rate of neutropenic fever in 137
patients receiving FEC-T; all affected patients were given
secondary prophylactic G-CSF and there were no further episodes
of sepsis. The authors, from hospitals across south-east England,
recommend the use of primary prophylaxis in all patients
receiving FEC-T. Ali et al (2008), from the Merseyside and
Cheshire Cancer Network, reported a 27% rate of febrile
neutropenia in 123 FEC-T recipients, including six patients who
had two episodes . Only 8% of patients had further sepsis following
secondary prophylaxis with G-CSF, and the authors suggest that
primary or secondary G-CSF should be considered for all patients
using FEC-T (Head et al, 2008).
CONCLUSION
Although breast cancer remains a common malignancy, the
outlook for women with early-stage disease has been transformed
since the Halsted days when radical surgery was the only
therapeutic option. Recent advances in chemotherapy for breast
cancer have culminated, in England and Wales, in the latest NICE
guidelines for the management of early and advanced disease.
However, effective use of UK-licensed and NICE-approved regi-
mens requires the development and full implementation of local
policies aimed not only at treatment delivery but also at strategies
for predicting, preventing and managing the complications of
chemotherapy, notably febrile neutropenia. Such policies, in
operation across every cancer network, would save lives and,
I believe, reinforce clinicians’ confidence in the regimens now at
our disposal.
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